<!-- Name:DistributionId Value:8744304 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 --> <!-- Name:CustomerId Value:1213020 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:cbc54773-430f-43a4-90ce-500f7bd31fbb --> The initial li... Read More...

<!-- Name:DistributionId Value:8739250 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 --> <!-- Name:CustomerId Value:1213020 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:f13a43e8-8203-4d70-a857-c39dbeb4c6bf --> NOT FOR DISTRI... Read More...

This export marks Avicanna’s 19th new international market for Avicanna and the 16th for Aureus branded products. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Jan. 17, 2023 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical ... Read More...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 30, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, internat... Read More...

TORONTO, Dec. 14, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it will be initiating an observational real-world evidence (“RW... Read More...

Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC beverage infuser under the Viola brand available in Ontario through the Ontario Cannabis Store and expanding into other adult use and medical ... Read More...

TORONTO, Oct. 31, 2022 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that it has entered into a extension agreement (the “Extension Agreement”) in conn... Read More...

TORONTO, Oct. 20, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has formalized its provisional patent application, entitled ... Read More...

Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical cannabis sales and on-going research with UHN TORONTO, Sept. 15, 2022 -- Avi... Read More...

Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform TORONTO, July 20, 2022 -- Avicanna Inc. ("Avicanna" or the "Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and comme... Read More...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, July 11, 2022 -- Avicanna Inc. ("Avicanna" or the "Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company f... Read More...

TORONTO, June 24, 2022 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the sale of its stake in Sativa Nativa S.A.S. (“Sativa Nativa”), which was... Read More...

This export marks the 16th international market entry for Avicanna and the first export of proprietary genetics into Africa. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, June 09, 2022 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopha... Read More...

Avicanna introduces the rare cannabinoid CBG into its RHO Phyto product formulary which includes oral, sublingual, and transdermal formulations RHO Phyto CBG products will be made available through various medical and adult-use channels across Canada by Q3 2022 TORONTO, April 28, 2022 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: A... Read More...

The exclusive distribution agreement includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio The products will be commercialized through Bio-Gate’s existing distribution channels with initial launches planned for Germany, Austria, and Switzerland in 2022 TORONTO, April 05, 2022 -- Avicanna Inc. (“Avicanna” or the “Com... Read More...

TORONTO, Feb. 14, 2022 -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has executed ... Read More...

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile Supply of Avicanna’s active pharmaceutical ingredients for existing commercial and pipeline of pharmaceutical products in South America TORONTO, Jan. 14, 2022 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FS... Read More...

TORONTO, Jan. 10, 2022 -- Avicanna USA Inc. together with Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the appointmen... Read More...

TORONTO, Jan. 04, 2022 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the appointment of Eileen McCormack to, and the resignation of Setu Pur... Read More...

First commercial export of Cannabigerol (CBG), a rare cannabinoid, into Czech Republic This export represents the 14th international market entrance for Avicanna products TORONTO, Dec. 24, 2021 -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manu... Read More...

The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across four international markets The initial launch of Pura H&W will include seven SKUs of proprietary products that will be available through e-commerce as well as cannabis and non-cannabis specific retailers TORONT... Read More...

re+PLAY is a sports performance and recovery-focused brand founded by NBA veteran Al Harrington with and evidence-based CBD formulations developed in partnership with Avicanna Products will be available across adult use channels in Alberta and Ontario and medical channels in partnership with Medical Cannabis by Shoppers™ This marks the 4t... Read More...

Proprietary formulations include a range of liquids, capsules, powders, and controlled release tablets utilizing Avicanna’s self-emulsifying drug delivery systems (SEDDS) technology The advanced formulations offer enhanced stability, bioavailability and controlled release of cannabinoids including (CBD, THC, CBG, CBN and THCv) Avicanna i... Read More...

TORONTO, Nov. 30, 2021 -- Avicanna Inc. ("Avicanna") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into a partnership with an established Argentine pharmaceutical com... Read More...

Starting with 3 SKUs, the advanced medical cannabis formulary will be available for the medical community and patients through prescriptionDistribution partnership with Bryden Stokes Limited includes initial focus on Barbados with plans to expand further into the Caribbean regionThird active country for RHO Phyto formulations and 13th int... Read More...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Nov. 11, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company ... Read More...

The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products. TORONTO, Oct. 22, 2021 -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutic... Read More...

This marks Avicanna’s first commercial exports of proprietary genetics in the form of feminized seeds into the Peruvian and the Argentine medical cannabis markets.Avicanna worked closely with the Colombian and Argentine ministries of agriculture to establish the phyto-sanitary requirements to allow for continuous supply to the emerging Ar... Read More...

Research findings originated from cannabinoid-based collaboration with leading epilepsy researcher, Dr. Peter Carlen, at UHN that is also supported by a Mitacs Accelerate program grant.Avicanna’s proprietary formulation showed promising pre-clinical results in reducing seizures and will be developed through the company’s pharmaceutical de... Read More...

Four SKUs of Pura Earth branded dermacosmetics have been successfully registered with ARCSA, imported into Ecuador, and will be distributed and commercialized through previously announced partnership with Spenta S.A.This marks the 12th country and market opening of Avicanna’s product offerings. /NOT FOR DISTRIBUTION TO UNITED STATES NEWS... Read More...

TORONTO, Sept. 13, 2021 -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the failure-to-file cease trade order (the "CTO") issued by the On... Read More...

This initial export to Brazil marks Avicanna’s first commercial export of psychoactive Cannabis Extracts into the emerging Brazilian medicinal cannabis market and the delivery of the initial purchase order from the previously announced three (3) year master supply agreement.This shipment also marks the 11th country to which SMGH has expor... Read More...

Initial listings of topical SKUs include 3 Pura Earth branded facial topical products and 1 RHO Phyto branded Extra Strength Deep Tissue GelAvicanna’s leadership in the emerging category of topicals, with listings now in 5 provinces, is attributed to the proprietary functional formulations and clinical evidence behind the products /NOT F... Read More...